 Petter Bjornstad
Concepts (454)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Nephropathies | 92 | 2026 | 322 | 26.780 |
Why?
| | Diabetes Mellitus, Type 2 | 82 | 2026 | 2588 | 11.620 |
Why?
| | Diabetes Mellitus, Type 1 | 86 | 2026 | 3922 | 10.390 |
Why?
| | Glomerular Filtration Rate | 73 | 2026 | 765 | 9.280 |
Why?
| | Kidney | 60 | 2026 | 1497 | 7.420 |
Why?
| | Insulin Resistance | 25 | 2026 | 1244 | 5.320 |
Why?
| | Renal Insufficiency, Chronic | 30 | 2026 | 668 | 4.900 |
Why?
| | Uric Acid | 23 | 2022 | 167 | 4.400 |
Why?
| | Albuminuria | 24 | 2026 | 189 | 4.190 |
Why?
| | Biomarkers | 42 | 2026 | 4295 | 2.990 |
Why?
| | Sodium-Glucose Transporter 2 | 14 | 2026 | 29 | 2.970 |
Why?
| | Cardiovascular Diseases | 19 | 2026 | 2187 | 2.810 |
Why?
| | Pediatric Obesity | 9 | 2025 | 638 | 2.720 |
Why?
| | Bariatric Surgery | 6 | 2026 | 252 | 2.720 |
Why?
| | Hemodynamics | 23 | 2025 | 1118 | 2.650 |
Why?
| | Metformin | 12 | 2025 | 329 | 2.630 |
Why?
| | Renal Insufficiency | 6 | 2023 | 172 | 2.550 |
Why?
| | Hypoglycemic Agents | 27 | 2026 | 1399 | 2.480 |
Why?
| | Coronary Artery Disease | 11 | 2022 | 749 | 2.370 |
Why?
| | Diabetic Angiopathies | 9 | 2019 | 264 | 2.300 |
Why?
| | Glucosides | 15 | 2026 | 56 | 2.270 |
Why?
| | Benzhydryl Compounds | 15 | 2026 | 81 | 2.230 |
Why?
| | Glycopeptides | 10 | 2021 | 44 | 2.120 |
Why?
| | Adolescent | 71 | 2026 | 22530 | 2.030 |
Why?
| | Vascular Calcification | 6 | 2022 | 110 | 2.020 |
Why?
| | Obesity, Morbid | 5 | 2020 | 293 | 1.960 |
Why?
| | Humans | 202 | 2026 | 145475 | 1.900 |
Why?
| | Renin-Angiotensin System | 10 | 2021 | 80 | 1.830 |
Why?
| | Kidney Diseases | 4 | 2025 | 425 | 1.780 |
Why?
| | Creatinine | 21 | 2026 | 515 | 1.670 |
Why?
| | Disease Progression | 26 | 2026 | 2864 | 1.550 |
Why?
| | Male | 123 | 2026 | 72843 | 1.540 |
Why?
| | Young Adult | 48 | 2026 | 14219 | 1.530 |
Why?
| | Sex Characteristics | 7 | 2025 | 782 | 1.530 |
Why?
| | Female | 118 | 2026 | 78845 | 1.440 |
Why?
| | Diabetic Ketoacidosis | 4 | 2025 | 209 | 1.360 |
Why?
| | Obesity | 14 | 2026 | 3116 | 1.260 |
Why?
| | Blood Glucose | 17 | 2026 | 2341 | 1.230 |
Why?
| | Calcinosis | 4 | 2015 | 234 | 1.230 |
Why?
| | Risk Factors | 40 | 2026 | 10885 | 1.220 |
Why?
| | Glucagon-Like Peptides | 3 | 2025 | 71 | 1.170 |
Why?
| | Adult | 66 | 2026 | 40777 | 1.160 |
Why?
| | Child | 40 | 2026 | 22707 | 1.110 |
Why?
| | Diabetic Cardiomyopathies | 4 | 2020 | 34 | 1.100 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 2 | 2026 | 138 | 1.060 |
Why?
| | Follow-Up Studies | 22 | 2026 | 5423 | 1.030 |
Why?
| | Adiposity | 6 | 2025 | 532 | 1.010 |
Why?
| | Hyperglycemia | 6 | 2025 | 379 | 1.000 |
Why?
| | Kidney Glomerulus | 7 | 2026 | 125 | 0.970 |
Why?
| | Middle Aged | 64 | 2026 | 36215 | 0.950 |
Why?
| | Cardio-Renal Syndrome | 1 | 2026 | 20 | 0.950 |
Why?
| | Hypertension | 9 | 2021 | 1273 | 0.950 |
Why?
| | Prognosis | 17 | 2026 | 4316 | 0.930 |
Why?
| | Janus Kinases | 1 | 2026 | 21 | 0.930 |
Why?
| | STAT Transcription Factors | 1 | 2026 | 25 | 0.930 |
Why?
| | Arterioles | 3 | 2024 | 52 | 0.920 |
Why?
| | Proteinuria | 3 | 2026 | 104 | 0.910 |
Why?
| | Atherosclerosis | 4 | 2018 | 409 | 0.910 |
Why?
| | Body Composition | 4 | 2026 | 693 | 0.910 |
Why?
| | Acute Kidney Injury | 6 | 2025 | 875 | 0.910 |
Why?
| | Exercise Tolerance | 3 | 2017 | 283 | 0.890 |
Why?
| | Fructose | 4 | 2021 | 132 | 0.880 |
Why?
| | Vascular Stiffness | 7 | 2022 | 486 | 0.880 |
Why?
| | Apolipoproteins B | 2 | 2015 | 47 | 0.880 |
Why?
| | Uromodulin | 3 | 2019 | 22 | 0.860 |
Why?
| | Hyperuricemia | 6 | 2021 | 47 | 0.850 |
Why?
| | Vasopressins | 3 | 2023 | 61 | 0.840 |
Why?
| | Iohexol | 3 | 2025 | 23 | 0.840 |
Why?
| | Adiponectin | 2 | 2016 | 241 | 0.830 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2024 | 41 | 0.830 |
Why?
| | Cross-Sectional Studies | 19 | 2025 | 5905 | 0.820 |
Why?
| | Case-Control Studies | 14 | 2025 | 3623 | 0.820 |
Why?
| | Iothalamic Acid | 1 | 2022 | 5 | 0.760 |
Why?
| | Kidney Tubules | 2 | 2021 | 118 | 0.760 |
Why?
| | Hyperoxia | 1 | 2024 | 96 | 0.750 |
Why?
| | Dyslipidemias | 5 | 2021 | 184 | 0.750 |
Why?
| | Kidney Failure, Chronic | 5 | 2026 | 599 | 0.740 |
Why?
| | Blood Pressure | 10 | 2025 | 1779 | 0.740 |
Why?
| | Diabetic Retinopathy | 4 | 2021 | 209 | 0.730 |
Why?
| | Prediabetic State | 1 | 2025 | 249 | 0.730 |
Why?
| | Cystatin C | 8 | 2023 | 66 | 0.720 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2024 | 219 | 0.720 |
Why?
| | Epidermal Growth Factor | 4 | 2026 | 162 | 0.710 |
Why?
| | Recombinant Fusion Proteins | 1 | 2024 | 666 | 0.690 |
Why?
| | Bone Density | 1 | 2025 | 487 | 0.670 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2024 | 235 | 0.640 |
Why?
| | Podocytes | 3 | 2026 | 80 | 0.630 |
Why?
| | Kidney Function Tests | 7 | 2026 | 156 | 0.620 |
Why?
| | Fasting | 3 | 2026 | 279 | 0.620 |
Why?
| | Oxygen Consumption | 3 | 2017 | 718 | 0.620 |
Why?
| | Triglycerides | 3 | 2022 | 520 | 0.610 |
Why?
| | Insulin | 11 | 2026 | 2512 | 0.600 |
Why?
| | Dried Blood Spot Testing | 2 | 2018 | 126 | 0.590 |
Why?
| | Pilot Projects | 8 | 2026 | 1891 | 0.590 |
Why?
| | Mitochondria | 1 | 2026 | 992 | 0.590 |
Why?
| | Vascular Resistance | 6 | 2020 | 370 | 0.590 |
Why?
| | Endothelial Cells | 4 | 2026 | 874 | 0.590 |
Why?
| | Cyclic GMP | 1 | 2019 | 90 | 0.580 |
Why?
| | Incidence | 11 | 2026 | 2923 | 0.580 |
Why?
| | Oxygen | 2 | 2024 | 978 | 0.580 |
Why?
| | Lipid Metabolism Disorders | 1 | 2018 | 4 | 0.570 |
Why?
| | Longevity | 6 | 2022 | 178 | 0.570 |
Why?
| | Coronary Vessels | 3 | 2017 | 246 | 0.570 |
Why?
| | Cardiotonic Agents | 1 | 2018 | 94 | 0.550 |
Why?
| | Aged | 39 | 2026 | 26153 | 0.550 |
Why?
| | Cohort Studies | 18 | 2025 | 6013 | 0.550 |
Why?
| | Leptin | 2 | 2017 | 248 | 0.540 |
Why?
| | Gastric Bypass | 1 | 2020 | 126 | 0.540 |
Why?
| | Hemofiltration | 1 | 2018 | 24 | 0.540 |
Why?
| | Weight Reduction Programs | 1 | 2019 | 140 | 0.540 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 48 | 0.530 |
Why?
| | Overweight | 3 | 2025 | 614 | 0.530 |
Why?
| | Cholesterol, HDL | 2 | 2015 | 201 | 0.530 |
Why?
| | Blood Vessels | 1 | 2018 | 167 | 0.510 |
Why?
| | Glucose | 5 | 2023 | 1048 | 0.510 |
Why?
| | Ventricular Function, Left | 3 | 2020 | 542 | 0.510 |
Why?
| | Inflammation | 3 | 2026 | 2878 | 0.500 |
Why?
| | Canagliflozin | 4 | 2026 | 11 | 0.490 |
Why?
| | Aorta | 2 | 2019 | 440 | 0.490 |
Why?
| | Up-Regulation | 2 | 2016 | 847 | 0.480 |
Why?
| | Nutrition Surveys | 1 | 2017 | 279 | 0.470 |
Why?
| | Cholesterol, LDL | 2 | 2014 | 360 | 0.470 |
Why?
| | Testosterone | 4 | 2026 | 416 | 0.460 |
Why?
| | Glucose Clamp Technique | 7 | 2026 | 199 | 0.450 |
Why?
| | Body Mass Index | 10 | 2026 | 2445 | 0.440 |
Why?
| | Drug Therapy, Combination | 6 | 2025 | 1044 | 0.440 |
Why?
| | Renal Circulation | 3 | 2021 | 75 | 0.430 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2014 | 7 | 0.430 |
Why?
| | Canada | 7 | 2022 | 431 | 0.420 |
Why?
| | Nephrotic Syndrome | 2 | 2026 | 43 | 0.420 |
Why?
| | Sodium | 5 | 2025 | 198 | 0.410 |
Why?
| | Natriuresis | 3 | 2025 | 13 | 0.410 |
Why?
| | Gastrectomy | 2 | 2026 | 166 | 0.400 |
Why?
| | Signal Transduction | 3 | 2026 | 5216 | 0.400 |
Why?
| | Echocardiography | 2 | 2018 | 647 | 0.400 |
Why?
| | Dietary Supplements | 1 | 2018 | 583 | 0.400 |
Why?
| | Pregnancy Outcome | 1 | 2017 | 503 | 0.400 |
Why?
| | Hypoxia | 2 | 2020 | 1199 | 0.390 |
Why?
| | Estradiol | 3 | 2026 | 515 | 0.390 |
Why?
| | Goals | 1 | 2015 | 184 | 0.380 |
Why?
| | Vasoconstriction | 3 | 2020 | 216 | 0.380 |
Why?
| | Patient Care Planning | 1 | 2014 | 170 | 0.380 |
Why?
| | Chitinase-3-Like Protein 1 | 2 | 2022 | 18 | 0.370 |
Why?
| | Brain | 1 | 2025 | 2947 | 0.370 |
Why?
| | Heart Failure | 3 | 2021 | 2326 | 0.370 |
Why?
| | Clinical Trials as Topic | 7 | 2025 | 1061 | 0.360 |
Why?
| | Histidine | 2 | 2022 | 66 | 0.360 |
Why?
| | Contrast Media | 1 | 2015 | 497 | 0.350 |
Why?
| | Age of Onset | 2 | 2025 | 555 | 0.350 |
Why?
| | Lipids | 2 | 2022 | 707 | 0.340 |
Why?
| | Prospective Studies | 11 | 2026 | 8057 | 0.340 |
Why?
| | Proteome | 2 | 2026 | 514 | 0.340 |
Why?
| | Albumins | 3 | 2022 | 119 | 0.330 |
Why?
| | Angiotensin II | 3 | 2020 | 101 | 0.330 |
Why?
| | Glucagon-Like Peptide 1 | 4 | 2026 | 149 | 0.320 |
Why?
| | Guideline Adherence | 1 | 2015 | 586 | 0.320 |
Why?
| | Absorptiometry, Photon | 2 | 2025 | 277 | 0.310 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 443 | 0.310 |
Why?
| | Lipocalin-2 | 2 | 2022 | 80 | 0.310 |
Why?
| | Double-Blind Method | 6 | 2026 | 2062 | 0.310 |
Why?
| | Precision Medicine | 2 | 2026 | 459 | 0.300 |
Why?
| | Animals | 19 | 2026 | 38030 | 0.300 |
Why?
| | Energy Metabolism | 2 | 2026 | 935 | 0.290 |
Why?
| | Linagliptin | 2 | 2026 | 5 | 0.290 |
Why?
| | Running | 2 | 2023 | 233 | 0.280 |
Why?
| | Pulse Wave Analysis | 5 | 2022 | 267 | 0.280 |
Why?
| | Biopsy | 4 | 2026 | 1082 | 0.270 |
Why?
| | Treatment Outcome | 12 | 2026 | 11772 | 0.270 |
Why?
| | Diabetes Complications | 2 | 2021 | 224 | 0.260 |
Why?
| | Magnetic Resonance Imaging | 6 | 2025 | 3904 | 0.250 |
Why?
| | Metabolic Syndrome | 3 | 2021 | 360 | 0.250 |
Why?
| | Time Factors | 7 | 2025 | 7123 | 0.250 |
Why?
| | Clusterin | 1 | 2026 | 12 | 0.250 |
Why?
| | Sex Factors | 5 | 2025 | 2105 | 0.240 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 3 | 2025 | 46 | 0.240 |
Why?
| | MEF2 Transcription Factors | 1 | 2026 | 51 | 0.240 |
Why?
| | Heat Stress Disorders | 2 | 2018 | 84 | 0.240 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2026 | 38 | 0.240 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 3 | 2021 | 88 | 0.230 |
Why?
| | Age Factors | 7 | 2019 | 3342 | 0.230 |
Why?
| | Diabetes Mellitus | 3 | 2021 | 1097 | 0.230 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2930 | 0.230 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 531 | 0.230 |
Why?
| | Gliclazide | 1 | 2025 | 2 | 0.230 |
Why?
| | Colorado | 4 | 2017 | 4554 | 0.220 |
Why?
| | Abdominal Fat | 1 | 2025 | 51 | 0.220 |
Why?
| | Osmolar Concentration | 3 | 2026 | 168 | 0.220 |
Why?
| | Leucine | 2 | 2024 | 116 | 0.220 |
Why?
| | Fatty Acid Binding Protein 3 | 1 | 2024 | 6 | 0.220 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2024 | 42 | 0.220 |
Why?
| | Early Diagnosis | 2 | 2017 | 251 | 0.220 |
Why?
| | Citric Acid Cycle | 1 | 2024 | 58 | 0.210 |
Why?
| | Predictive Value of Tests | 4 | 2018 | 2121 | 0.210 |
Why?
| | Renin | 2 | 2022 | 33 | 0.210 |
Why?
| | Diuretics | 2 | 2023 | 68 | 0.210 |
Why?
| | Androgen Antagonists | 1 | 2025 | 91 | 0.210 |
Why?
| | Gray Matter | 1 | 2025 | 92 | 0.210 |
Why?
| | Lipoproteins | 2 | 2022 | 166 | 0.210 |
Why?
| | Endothelin Receptor Antagonists | 2 | 2024 | 61 | 0.210 |
Why?
| | Blood Proteins | 1 | 2026 | 239 | 0.200 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2026 | 1747 | 0.200 |
Why?
| | Extracellular Vesicles | 1 | 2026 | 171 | 0.200 |
Why?
| | Receptors, Vasopressin | 2 | 2021 | 20 | 0.200 |
Why?
| | Gonadal Steroid Hormones | 1 | 2024 | 143 | 0.200 |
Why?
| | Consensus | 2 | 2022 | 477 | 0.200 |
Why?
| | Mineralocorticoid Receptor Antagonists | 2 | 2024 | 69 | 0.200 |
Why?
| | Inappropriate ADH Syndrome | 1 | 2023 | 7 | 0.190 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2024 | 147 | 0.190 |
Why?
| | Nephrosis, Lipoid | 1 | 2023 | 10 | 0.190 |
Why?
| | Cysts | 1 | 2024 | 112 | 0.190 |
Why?
| | Fluorocarbons | 1 | 2024 | 120 | 0.190 |
Why?
| | Membrane Glycoproteins | 1 | 2026 | 499 | 0.190 |
Why?
| | Pancreas | 1 | 2025 | 341 | 0.190 |
Why?
| | Transcriptome | 2 | 2026 | 1038 | 0.190 |
Why?
| | Hyponatremia | 1 | 2023 | 43 | 0.190 |
Why?
| | Single-Cell Analysis | 1 | 2026 | 362 | 0.190 |
Why?
| | Malates | 1 | 2022 | 8 | 0.180 |
Why?
| | Fumarates | 1 | 2022 | 10 | 0.180 |
Why?
| | Longitudinal Studies | 5 | 2024 | 2953 | 0.180 |
Why?
| | Threonine | 1 | 2022 | 44 | 0.180 |
Why?
| | Iodine Radioisotopes | 1 | 2022 | 136 | 0.180 |
Why?
| | Carboxylic Acids | 1 | 2022 | 31 | 0.180 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2023 | 199 | 0.180 |
Why?
| | Pathology, Clinical | 1 | 2022 | 29 | 0.180 |
Why?
| | Patient Participation | 1 | 2025 | 439 | 0.180 |
Why?
| | Phenylalanine | 1 | 2022 | 69 | 0.180 |
Why?
| | Rats | 2 | 2024 | 5584 | 0.180 |
Why?
| | Heart | 1 | 2025 | 626 | 0.170 |
Why?
| | Chemokine CCL2 | 1 | 2022 | 112 | 0.170 |
Why?
| | Amino Acids | 2 | 2024 | 519 | 0.170 |
Why?
| | Arizona | 1 | 2021 | 80 | 0.170 |
Why?
| | Health Status Disparities | 1 | 2024 | 321 | 0.170 |
Why?
| | Weight Loss | 3 | 2026 | 858 | 0.170 |
Why?
| | Glycine | 1 | 2022 | 186 | 0.170 |
Why?
| | Risk Assessment | 6 | 2026 | 3747 | 0.160 |
Why?
| | Mice | 7 | 2026 | 18329 | 0.160 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2025 | 779 | 0.160 |
Why?
| | Oxidation-Reduction | 1 | 2024 | 1067 | 0.160 |
Why?
| | p-Aminohippuric Acid | 1 | 2020 | 5 | 0.160 |
Why?
| | Tryptophan | 1 | 2022 | 182 | 0.160 |
Why?
| | Interleukin-18 | 1 | 2022 | 234 | 0.160 |
Why?
| | Multivariate Analysis | 2 | 2014 | 1547 | 0.160 |
Why?
| | Nephrosis | 1 | 2020 | 6 | 0.160 |
Why?
| | Furosemide | 1 | 2020 | 37 | 0.160 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2021 | 109 | 0.160 |
Why?
| | Asymptomatic Diseases | 2 | 2019 | 104 | 0.160 |
Why?
| | Japan | 5 | 2017 | 149 | 0.160 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2025 | 116 | 0.160 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2024 | 229 | 0.150 |
Why?
| | Diabetic Neuropathies | 1 | 2021 | 100 | 0.150 |
Why?
| | Machine Learning | 1 | 2026 | 587 | 0.150 |
Why?
| | Transgender Persons | 1 | 2023 | 210 | 0.150 |
Why?
| | Calcium Channel Blockers | 1 | 2021 | 166 | 0.150 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2019 | 11 | 0.150 |
Why?
| | Body Water | 1 | 2019 | 23 | 0.150 |
Why?
| | Diabetic Foot | 1 | 2019 | 25 | 0.150 |
Why?
| | Models, Biological | 3 | 2016 | 1764 | 0.150 |
Why?
| | Oxidative Stress | 1 | 2026 | 1356 | 0.150 |
Why?
| | Multicenter Studies as Topic | 3 | 2025 | 412 | 0.150 |
Why?
| | Glycolysis | 1 | 2021 | 340 | 0.150 |
Why?
| | Glomerulonephritis | 1 | 2019 | 44 | 0.150 |
Why?
| | Glycosides | 1 | 2019 | 43 | 0.150 |
Why?
| | Blood Chemical Analysis | 1 | 2019 | 109 | 0.140 |
Why?
| | Postmenopause | 1 | 2021 | 392 | 0.140 |
Why?
| | beta 2-Microglobulin | 1 | 2018 | 48 | 0.140 |
Why?
| | Software | 2 | 2025 | 680 | 0.140 |
Why?
| | Myocardial Contraction | 1 | 2020 | 293 | 0.140 |
Why?
| | Proof of Concept Study | 3 | 2025 | 89 | 0.140 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2018 | 75 | 0.140 |
Why?
| | Cell Proliferation | 1 | 2026 | 2507 | 0.140 |
Why?
| | Body Temperature Regulation | 1 | 2019 | 105 | 0.140 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 30 | 0.140 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 170 | 0.140 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 43 | 0.140 |
Why?
| | Allopurinol | 1 | 2018 | 70 | 0.140 |
Why?
| | Child, Preschool | 4 | 2025 | 11853 | 0.130 |
Why?
| | Obesity, Metabolically Benign | 1 | 2017 | 4 | 0.130 |
Why?
| | Prehypertension | 1 | 2017 | 27 | 0.130 |
Why?
| | Glucose Tolerance Test | 2 | 2019 | 360 | 0.130 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2017 | 41 | 0.130 |
Why?
| | Hyperthermia, Induced | 1 | 2018 | 120 | 0.130 |
Why?
| | Urinary Calculi | 1 | 2017 | 10 | 0.130 |
Why?
| | Life Style | 1 | 2019 | 485 | 0.130 |
Why?
| | Peptide Fragments | 1 | 2021 | 693 | 0.130 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2016 | 15 | 0.120 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2020 | 394 | 0.120 |
Why?
| | Magnetic Resonance Angiography | 1 | 2018 | 251 | 0.120 |
Why?
| | Morbidity | 1 | 2017 | 322 | 0.120 |
Why?
| | Blood Banks | 1 | 2016 | 50 | 0.120 |
Why?
| | Dehydration | 1 | 2016 | 58 | 0.120 |
Why?
| | Cardiorespiratory Fitness | 1 | 2017 | 74 | 0.120 |
Why?
| | Regional Blood Flow | 1 | 2018 | 514 | 0.120 |
Why?
| | Vasodilation | 1 | 2020 | 521 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 767 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 477 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 2 | 2018 | 2769 | 0.120 |
Why?
| | Disease Models, Animal | 5 | 2021 | 4560 | 0.120 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2016 | 15 | 0.120 |
Why?
| | Linear Models | 2 | 2017 | 845 | 0.120 |
Why?
| | Logistic Models | 3 | 2017 | 2134 | 0.120 |
Why?
| | Survival Rate | 2 | 2017 | 2090 | 0.120 |
Why?
| | Heart Rate | 1 | 2019 | 855 | 0.110 |
Why?
| | Cognition | 1 | 2024 | 1266 | 0.110 |
Why?
| | Echocardiography, Doppler | 1 | 2016 | 115 | 0.110 |
Why?
| | Hot Temperature | 1 | 2018 | 396 | 0.110 |
Why?
| | Gene Expression Regulation | 2 | 2026 | 2597 | 0.110 |
Why?
| | Filtration | 1 | 2015 | 68 | 0.110 |
Why?
| | Liver Diseases | 1 | 2018 | 305 | 0.110 |
Why?
| | Apolipoproteins | 1 | 2014 | 38 | 0.110 |
Why?
| | Integrin beta1 | 2 | 2026 | 33 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 2018 | 820 | 0.110 |
Why?
| | Blood Pressure Determination | 1 | 2015 | 145 | 0.100 |
Why?
| | Phenotype | 1 | 2022 | 3155 | 0.100 |
Why?
| | Purines | 1 | 2015 | 187 | 0.100 |
Why?
| | Achievement | 1 | 2014 | 58 | 0.100 |
Why?
| | Stress, Mechanical | 1 | 2016 | 494 | 0.100 |
Why?
| | Retrospective Studies | 9 | 2026 | 17291 | 0.100 |
Why?
| | Immunity, Innate | 1 | 2019 | 835 | 0.100 |
Why?
| | Gene Regulatory Networks | 2 | 2026 | 317 | 0.100 |
Why?
| | Liver | 2 | 2021 | 1896 | 0.100 |
Why?
| | Primary Prevention | 1 | 2015 | 219 | 0.090 |
Why?
| | Exercise Test | 1 | 2016 | 630 | 0.090 |
Why?
| | Research Design | 1 | 2019 | 1137 | 0.090 |
Why?
| | Adenosine Triphosphate | 1 | 2015 | 500 | 0.090 |
Why?
| | Cholesterol | 1 | 2014 | 408 | 0.090 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 857 | 0.090 |
Why?
| | Cross-Over Studies | 2 | 2026 | 608 | 0.090 |
Why?
| | United States | 3 | 2024 | 16098 | 0.090 |
Why?
| | Antihypertensive Agents | 1 | 2016 | 519 | 0.090 |
Why?
| | Regression Analysis | 1 | 2014 | 1001 | 0.090 |
Why?
| | RNA, Messenger | 1 | 2019 | 2803 | 0.090 |
Why?
| | Aged, 80 and over | 3 | 2018 | 8333 | 0.080 |
Why?
| | Vascular Diseases | 1 | 2013 | 252 | 0.080 |
Why?
| | Feasibility Studies | 1 | 2015 | 1111 | 0.080 |
Why?
| | Exercise | 1 | 2022 | 2198 | 0.080 |
Why?
| | Hematocrit | 2 | 2021 | 108 | 0.080 |
Why?
| | Societies, Medical | 1 | 2015 | 899 | 0.080 |
Why?
| | Ambulatory Care | 1 | 2015 | 609 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1581 | 0.070 |
Why?
| | Proteomics | 2 | 2026 | 1188 | 0.070 |
Why?
| | Fructokinases | 2 | 2021 | 42 | 0.070 |
Why?
| | Registries | 1 | 2016 | 2406 | 0.070 |
Why?
| | Prevalence | 3 | 2019 | 2865 | 0.060 |
Why?
| | Reproducibility of Results | 1 | 2015 | 3413 | 0.060 |
Why?
| | Peptides | 2 | 2026 | 998 | 0.060 |
Why?
| | Fibrosis | 2 | 2021 | 559 | 0.060 |
Why?
| | Mesangial Cells | 1 | 2026 | 4 | 0.060 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2026 | 75 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2026 | 3124 | 0.060 |
Why?
| | Peptide YY | 1 | 2026 | 28 | 0.060 |
Why?
| | Infant | 2 | 2025 | 10077 | 0.060 |
Why?
| | Receptors, Complement | 1 | 2026 | 123 | 0.060 |
Why?
| | Nephrectomy | 1 | 2026 | 163 | 0.050 |
Why?
| | C-Peptide | 1 | 2026 | 190 | 0.050 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2026 | 177 | 0.050 |
Why?
| | Organ Size | 1 | 2025 | 461 | 0.050 |
Why?
| | United Kingdom | 1 | 2025 | 344 | 0.050 |
Why?
| | Postprandial Period | 1 | 2025 | 114 | 0.050 |
Why?
| | Isoleucine | 1 | 2024 | 15 | 0.050 |
Why?
| | Propensity Score | 1 | 2026 | 377 | 0.050 |
Why?
| | Pregnancy | 1 | 2017 | 7202 | 0.050 |
Why?
| | Cell Communication | 1 | 2026 | 328 | 0.050 |
Why?
| | Living Donors | 1 | 2026 | 282 | 0.050 |
Why?
| | Valine | 1 | 2024 | 83 | 0.050 |
Why?
| | Obesity, Abdominal | 1 | 2024 | 47 | 0.050 |
Why?
| | Doxorubicin | 1 | 2026 | 401 | 0.050 |
Why?
| | Mice, Inbred C57BL | 3 | 2021 | 5983 | 0.050 |
Why?
| | Antibodies | 1 | 2025 | 397 | 0.050 |
Why?
| | Bromocriptine | 1 | 2022 | 31 | 0.050 |
Why?
| | Environmental Pollutants | 1 | 2024 | 139 | 0.050 |
Why?
| | Fatty Acids | 1 | 2026 | 457 | 0.050 |
Why?
| | Tandem Mass Spectrometry | 1 | 2026 | 572 | 0.050 |
Why?
| | Aging | 1 | 2014 | 1969 | 0.050 |
Why?
| | RNA, Transfer | 1 | 2024 | 143 | 0.050 |
Why?
| | Benzbromarone | 1 | 2022 | 1 | 0.050 |
Why?
| | NF-kappa B | 1 | 2026 | 666 | 0.050 |
Why?
| | Cytokines | 2 | 2021 | 2067 | 0.050 |
Why?
| | Infant, Newborn | 1 | 2014 | 6447 | 0.050 |
Why?
| | Aldosterone | 1 | 2022 | 42 | 0.050 |
Why?
| | Glycoproteins | 1 | 2024 | 354 | 0.040 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2021 | 27 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2026 | 1217 | 0.040 |
Why?
| | Inulin | 1 | 2021 | 12 | 0.040 |
Why?
| | Adenine | 1 | 2023 | 339 | 0.040 |
Why?
| | Hep G2 Cells | 1 | 2021 | 73 | 0.040 |
Why?
| | Drinking | 1 | 2021 | 44 | 0.040 |
Why?
| | Serum Albumin | 1 | 2021 | 147 | 0.040 |
Why?
| | Insulin Infusion Systems | 1 | 2026 | 480 | 0.040 |
Why?
| | Uricosuric Agents | 1 | 2020 | 2 | 0.040 |
Why?
| | Diuretics, Osmotic | 1 | 2020 | 2 | 0.040 |
Why?
| | Mendelian Randomization Analysis | 1 | 2020 | 55 | 0.040 |
Why?
| | Cell Hypoxia | 1 | 2021 | 247 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2023 | 454 | 0.040 |
Why?
| | Chemokines | 1 | 2021 | 217 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2024 | 578 | 0.040 |
Why?
| | Diastole | 1 | 2020 | 146 | 0.040 |
Why?
| | Systole | 1 | 2020 | 181 | 0.040 |
Why?
| | Cytoprotection | 1 | 2019 | 56 | 0.040 |
Why?
| | Netherlands | 1 | 2019 | 84 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2023 | 558 | 0.040 |
Why?
| | Recurrence | 1 | 2023 | 1138 | 0.040 |
Why?
| | Lipopolysaccharides | 1 | 2023 | 858 | 0.040 |
Why?
| | Drug Interactions | 1 | 2021 | 405 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 149 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2026 | 1767 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2024 | 1134 | 0.040 |
Why?
| | Length of Stay | 1 | 2025 | 1349 | 0.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2020 | 214 | 0.040 |
Why?
| | Critical Illness | 1 | 2025 | 900 | 0.030 |
Why?
| | Incretins | 1 | 2018 | 21 | 0.030 |
Why?
| | Renal Elimination | 1 | 2018 | 5 | 0.030 |
Why?
| | Macular Edema | 1 | 2018 | 49 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2021 | 506 | 0.030 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 1 | 2018 | 16 | 0.030 |
Why?
| | Photography | 1 | 2018 | 119 | 0.030 |
Why?
| | Xanthine Oxidase | 1 | 2018 | 79 | 0.030 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 467 | 0.030 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2018 | 75 | 0.030 |
Why?
| | Diet Therapy | 1 | 2018 | 36 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2019 | 138 | 0.030 |
Why?
| | Renal Dialysis | 1 | 2021 | 466 | 0.030 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2017 | 69 | 0.030 |
Why?
| | Lipoproteins, LDL | 1 | 2017 | 119 | 0.030 |
Why?
| | Anti-Obesity Agents | 1 | 2018 | 67 | 0.030 |
Why?
| | Renal Plasma Flow, Effective | 1 | 2016 | 1 | 0.030 |
Why?
| | Blood Urea Nitrogen | 1 | 2016 | 53 | 0.030 |
Why?
| | Thiazolidinediones | 1 | 2018 | 139 | 0.030 |
Why?
| | Aldehyde Reductase | 1 | 2016 | 31 | 0.030 |
Why?
| | Telemedicine | 1 | 2026 | 961 | 0.030 |
Why?
| | Water-Electrolyte Balance | 1 | 2016 | 37 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2018 | 428 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2021 | 776 | 0.030 |
Why?
| | Ammonia | 1 | 2016 | 61 | 0.030 |
Why?
| | Tomography, Optical Coherence | 1 | 2018 | 271 | 0.030 |
Why?
| | Age Distribution | 1 | 2017 | 403 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 387 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1327 | 0.030 |
Why?
| | Collagen | 1 | 2018 | 457 | 0.030 |
Why?
| | Waist Circumference | 1 | 2015 | 143 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1266 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2019 | 701 | 0.020 |
Why?
| | Complement Activation | 1 | 2016 | 399 | 0.020 |
Why?
| | Circadian Rhythm | 1 | 2017 | 512 | 0.020 |
Why?
| | Exercise Therapy | 1 | 2018 | 475 | 0.020 |
Why?
| | Heart Ventricles | 1 | 2018 | 756 | 0.020 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 180 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1661 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2017 | 2524 | 0.020 |
Why?
| | Models, Statistical | 1 | 2015 | 671 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1490 | 0.020 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2014 | 265 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1845 | 0.020 |
Why?
| | Hospitalization | 1 | 2017 | 2460 | 0.020 |
Why?
| | Neoplasms | 1 | 2014 | 2906 | 0.010 |
Why?
|
|
Bjornstad's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|